Cargando…

A study protocol for the evaluation of occupational mutagenic/carcinogenic risks in subjects exposed to antineoplastic drugs: a multicentric project

BACKGROUND: Some industrial hygiene studies have assessed occupational exposure to antineoplastic drugs; other epidemiological investigations have detected various toxicological effects in exposure groups labeled with the job title. In no research has the same population been studied both environmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Moretti, Massimo, Bonfiglioli, Roberta, Feretti, Donatella, Pavanello, Sofia, Mussi, Francesca, Grollino, Maria G, Villarini, Milena, Barbieri, Anna, Ceretti, Elisabetta, Carrieri, Mariella, Buschini, Annamaria, Appolloni, Massimo, Dominici, Luca, Sabatini, Laura, Gelatti, Umberto, Bartolucci, Giovanni B, Poli, Paola, Stronati, Laura, Mastrangelo, Giuseppe, Monarca, Silvano
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3074546/
https://www.ncbi.nlm.nih.gov/pubmed/21450074
http://dx.doi.org/10.1186/1471-2458-11-195
_version_ 1782201723848228864
author Moretti, Massimo
Bonfiglioli, Roberta
Feretti, Donatella
Pavanello, Sofia
Mussi, Francesca
Grollino, Maria G
Villarini, Milena
Barbieri, Anna
Ceretti, Elisabetta
Carrieri, Mariella
Buschini, Annamaria
Appolloni, Massimo
Dominici, Luca
Sabatini, Laura
Gelatti, Umberto
Bartolucci, Giovanni B
Poli, Paola
Stronati, Laura
Mastrangelo, Giuseppe
Monarca, Silvano
author_facet Moretti, Massimo
Bonfiglioli, Roberta
Feretti, Donatella
Pavanello, Sofia
Mussi, Francesca
Grollino, Maria G
Villarini, Milena
Barbieri, Anna
Ceretti, Elisabetta
Carrieri, Mariella
Buschini, Annamaria
Appolloni, Massimo
Dominici, Luca
Sabatini, Laura
Gelatti, Umberto
Bartolucci, Giovanni B
Poli, Paola
Stronati, Laura
Mastrangelo, Giuseppe
Monarca, Silvano
author_sort Moretti, Massimo
collection PubMed
description BACKGROUND: Some industrial hygiene studies have assessed occupational exposure to antineoplastic drugs; other epidemiological investigations have detected various toxicological effects in exposure groups labeled with the job title. In no research has the same population been studied both environmentally and epidemiologically. The protocol of the epidemiological study presented here uses an integrated environmental and biological monitoring approach. The aim is to assess in hospital nurses preparing and/or administering therapy to cancer patients the current level of occupational exposure to antineoplastic drugs, DNA and chromosome damage as cancer predictive effects, and the association between the two. METHODS/DESIGN: About 80 healthy non-smoking female nurses, who job it is to prepare or handle antineoplastic drugs, and a reference group of about 80 healthy non-smoking female nurses not occupationally exposed to chemicals will be examined simultaneously in a cross-sectional study. All the workers will be recruited from five hospitals in northern and central Italy after their informed consent has been obtained. Evaluation of surface contamination and dermal exposure to antineoplastic drugs will be assessed by determining cyclophosphamide on selected surfaces (wipes) and on the exposed nurses' clothes (pads). The concentration of unmetabolized cyclophosphamide as a biomarker of internal dose will be measured in end-shift urine samples from exposed nurses. Biomarkers of effect and susceptibility will be assessed in exposed and unexposed nurses: urinary concentration of 8-hydroxy-2-deoxyguanosine; DNA damage detected using the single-cell microgel electrophoresis (comet) assay in peripheral white blood cells; micronuclei and chromosome aberrations in peripheral blood lymphocytes. Genetic polymorphisms for enzymes involved in metabolic detoxification (i.e. glutathione S-transferases) will also be analysed. Using standardized questionnaires, occupational exposure will be determined in exposed nurses only, whereas potential confounders (medicine consumption, lifestyle habits, diet and other non-occupational exposures) will be assessed in both groups of hospital workers. Statistical analysis will be performed to ascertain the association between occupational exposure to antineoplastic drugs and biomarkers of DNA and chromosome damage, after taking into account the effects of individual genetic susceptibility, and the presence of confounding exposures. DISCUSSION: The findings of the study will be useful in updating prevention procedures for handling antineoplastic drugs.
format Text
id pubmed-3074546
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30745462011-04-13 A study protocol for the evaluation of occupational mutagenic/carcinogenic risks in subjects exposed to antineoplastic drugs: a multicentric project Moretti, Massimo Bonfiglioli, Roberta Feretti, Donatella Pavanello, Sofia Mussi, Francesca Grollino, Maria G Villarini, Milena Barbieri, Anna Ceretti, Elisabetta Carrieri, Mariella Buschini, Annamaria Appolloni, Massimo Dominici, Luca Sabatini, Laura Gelatti, Umberto Bartolucci, Giovanni B Poli, Paola Stronati, Laura Mastrangelo, Giuseppe Monarca, Silvano BMC Public Health Study Protocol BACKGROUND: Some industrial hygiene studies have assessed occupational exposure to antineoplastic drugs; other epidemiological investigations have detected various toxicological effects in exposure groups labeled with the job title. In no research has the same population been studied both environmentally and epidemiologically. The protocol of the epidemiological study presented here uses an integrated environmental and biological monitoring approach. The aim is to assess in hospital nurses preparing and/or administering therapy to cancer patients the current level of occupational exposure to antineoplastic drugs, DNA and chromosome damage as cancer predictive effects, and the association between the two. METHODS/DESIGN: About 80 healthy non-smoking female nurses, who job it is to prepare or handle antineoplastic drugs, and a reference group of about 80 healthy non-smoking female nurses not occupationally exposed to chemicals will be examined simultaneously in a cross-sectional study. All the workers will be recruited from five hospitals in northern and central Italy after their informed consent has been obtained. Evaluation of surface contamination and dermal exposure to antineoplastic drugs will be assessed by determining cyclophosphamide on selected surfaces (wipes) and on the exposed nurses' clothes (pads). The concentration of unmetabolized cyclophosphamide as a biomarker of internal dose will be measured in end-shift urine samples from exposed nurses. Biomarkers of effect and susceptibility will be assessed in exposed and unexposed nurses: urinary concentration of 8-hydroxy-2-deoxyguanosine; DNA damage detected using the single-cell microgel electrophoresis (comet) assay in peripheral white blood cells; micronuclei and chromosome aberrations in peripheral blood lymphocytes. Genetic polymorphisms for enzymes involved in metabolic detoxification (i.e. glutathione S-transferases) will also be analysed. Using standardized questionnaires, occupational exposure will be determined in exposed nurses only, whereas potential confounders (medicine consumption, lifestyle habits, diet and other non-occupational exposures) will be assessed in both groups of hospital workers. Statistical analysis will be performed to ascertain the association between occupational exposure to antineoplastic drugs and biomarkers of DNA and chromosome damage, after taking into account the effects of individual genetic susceptibility, and the presence of confounding exposures. DISCUSSION: The findings of the study will be useful in updating prevention procedures for handling antineoplastic drugs. BioMed Central 2011-03-30 /pmc/articles/PMC3074546/ /pubmed/21450074 http://dx.doi.org/10.1186/1471-2458-11-195 Text en Copyright ©2011 Moretti et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Study Protocol
Moretti, Massimo
Bonfiglioli, Roberta
Feretti, Donatella
Pavanello, Sofia
Mussi, Francesca
Grollino, Maria G
Villarini, Milena
Barbieri, Anna
Ceretti, Elisabetta
Carrieri, Mariella
Buschini, Annamaria
Appolloni, Massimo
Dominici, Luca
Sabatini, Laura
Gelatti, Umberto
Bartolucci, Giovanni B
Poli, Paola
Stronati, Laura
Mastrangelo, Giuseppe
Monarca, Silvano
A study protocol for the evaluation of occupational mutagenic/carcinogenic risks in subjects exposed to antineoplastic drugs: a multicentric project
title A study protocol for the evaluation of occupational mutagenic/carcinogenic risks in subjects exposed to antineoplastic drugs: a multicentric project
title_full A study protocol for the evaluation of occupational mutagenic/carcinogenic risks in subjects exposed to antineoplastic drugs: a multicentric project
title_fullStr A study protocol for the evaluation of occupational mutagenic/carcinogenic risks in subjects exposed to antineoplastic drugs: a multicentric project
title_full_unstemmed A study protocol for the evaluation of occupational mutagenic/carcinogenic risks in subjects exposed to antineoplastic drugs: a multicentric project
title_short A study protocol for the evaluation of occupational mutagenic/carcinogenic risks in subjects exposed to antineoplastic drugs: a multicentric project
title_sort study protocol for the evaluation of occupational mutagenic/carcinogenic risks in subjects exposed to antineoplastic drugs: a multicentric project
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3074546/
https://www.ncbi.nlm.nih.gov/pubmed/21450074
http://dx.doi.org/10.1186/1471-2458-11-195
work_keys_str_mv AT morettimassimo astudyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject
AT bonfiglioliroberta astudyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject
AT ferettidonatella astudyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject
AT pavanellosofia astudyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject
AT mussifrancesca astudyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject
AT grollinomariag astudyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject
AT villarinimilena astudyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject
AT barbierianna astudyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject
AT cerettielisabetta astudyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject
AT carrierimariella astudyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject
AT buschiniannamaria astudyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject
AT appollonimassimo astudyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject
AT dominiciluca astudyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject
AT sabatinilaura astudyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject
AT gelattiumberto astudyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject
AT bartoluccigiovannib astudyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject
AT polipaola astudyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject
AT stronatilaura astudyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject
AT mastrangelogiuseppe astudyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject
AT monarcasilvano astudyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject
AT morettimassimo studyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject
AT bonfiglioliroberta studyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject
AT ferettidonatella studyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject
AT pavanellosofia studyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject
AT mussifrancesca studyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject
AT grollinomariag studyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject
AT villarinimilena studyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject
AT barbierianna studyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject
AT cerettielisabetta studyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject
AT carrierimariella studyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject
AT buschiniannamaria studyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject
AT appollonimassimo studyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject
AT dominiciluca studyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject
AT sabatinilaura studyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject
AT gelattiumberto studyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject
AT bartoluccigiovannib studyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject
AT polipaola studyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject
AT stronatilaura studyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject
AT mastrangelogiuseppe studyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject
AT monarcasilvano studyprotocolfortheevaluationofoccupationalmutageniccarcinogenicrisksinsubjectsexposedtoantineoplasticdrugsamulticentricproject